RXi Pharmaceuticals Corp. (NASDAQ: RXII) is a biotechnology company focused on discovering and developing innovative therapeutics that address high-unmet medical needs, primarily in the area of dermatology and ophthalmology. Its discovery and clinical development programs are based on siRNA technology as well as immunotherapy agents, and includes its proprietary, self-delivering RNAi (sd-rxRNA) compounds for the treatment of dermal and retinal scarring. It also includes an immunomodulator, Samcyprone, a proprietary topical formulation of diphenylcyclopropenone (DPCP) for the treatment of such disorders as alopecia areata, warts and cutaneous metastases of melanoma. For more information, visit the company’s website at www.rxipharma.com